Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05628389
Other study ID # IRB202202537 -N
Secondary ID R01CA262319
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2023
Est. completion date August 31, 2027

Study information

Verified date June 2023
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The tobacco use burden in Lebanon is exceptionally high: 35% of adults are current cigarette smokers and 39% are current waterpipe smokers. Although the World Health Organization endorses evidence-based interventions for population-level tobacco dependence treatment, recommended treatments are not integrated as a routine part of primary care in Lebanon, as is the case in other low-resource settings. The objective of this proposal is to evaluate the comparative effectiveness of promising multi-component interventions for implementing evidence-based cessation treatment in Lebanon's national system of primary health care centers.


Description:

The research team will conduct a group-randomized trial comparing three arms: 1) Ask about tobacco use, advise to quit, assist with brief counseling (AAA) as standard care; 2) Ask, advise, connect to phone-based counseling (AAC); and 3) AAC+ Nicotine Replacement Therapy (NRT). Our central hypothesis is that connecting patients to phone-based counseling with cessation medication is the most effective alternative. The hybrid design is informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework which emphasizes key steps and multilevel factors to optimize implementation success. The following specific aims will be pursued: 1) adapt and tailor an existing smoking cessation program to deliver phone-based counseling to smokers in Lebanon; 2) test the effectiveness and cost-effectiveness of a referral-based program that delivers smoking cessation services to primary care patients; and 3) identify the multilevel determinants of implementation and sustainability using mixed methods.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1500
Est. completion date August 31, 2027
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18+ - A current daily cigarette smoker and/or a regular waterpipe smoker (smokes at least 1-2 times/week). - Not pregnant - Reachable by phone - Interested in quitting - Lives in Greater Beirut Area Exclusion Criteria: - Patients who smoke other tobacco products including vape, IQOS and others exclusively. - Any patient below 18 years old. - Cigarette smokers who do not smoke on daily basis. - Waterpipe smokers who smoke less than once/weekly

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Educational materials
Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.
Phone counseling
Cessation counseling to address insufficient patient self-efficacy and motivation.
Drug:
Nicotine Replacement Therapy
Nicotine patches to address nicotine withdrawal symptoms in patients.
Behavioral:
Provider training
Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.
Electronic reminders
Electronic reminders to address the lack of integration of AAA/AAC into practice.

Locations

Country Name City State
Lebanon American University of Beirut Medical Center Hamra Beirut

Sponsors (2)

Lead Sponsor Collaborator
University of Florida National Cancer Institute (NCI)

Country where clinical trial is conducted

Lebanon, 

Outcome

Type Measure Description Time frame Safety issue
Other Self-reported abstinence Continuous abstinence, quit attempts, smoking reduction 1, 3, 6 months
Primary 7-day smoking abstinence Carbon monoxide confirmed-abstinence from smoking in the last 7 days days prior to assessment 6 Months
See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT04617444 - The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function N/A
Completed NCT02796391 - Facilitating Smoking Cessation With Reduced Nicotine Cigarettes Phase 2
Completed NCT03397511 - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City N/A
Not yet recruiting NCT05188287 - A Culturally Tailored Smartphone Application for African American Smokers N/A
Recruiting NCT05264428 - The Effect of Honey on Lessening the Withdrawal Symptoms N/A
Completed NCT04133064 - Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study N/A
Completed NCT03187730 - Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants Phase 4
Completed NCT03474783 - To Explore the Factors Affecting the Effectiveness of Smoking Cessation N/A
Completed NCT04635358 - Feasibility Study of Smoking Cessation for the Staff of a Hospital Center N/A
Terminated NCT03670264 - BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation N/A
Completed NCT02905656 - Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02997657 - Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial N/A
Completed NCT02562521 - A Smoking Cessation Intervention for Yale Dining Employees Phase 4
Completed NCT02239770 - Pharmacokinetics of Nicotine Film in Smokers N/A
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A
Enrolling by invitation NCT02218944 - Smoking Response Inhibition Training N/A
Completed NCT02230384 - Novel Smoking Cessation Drug for Schizophrenia Phase 2